Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172060 | 0.88 | DHFR (0.47) | SMN1; SMN2ASH1LNPC1RAB9AALDH1A1 | |
| SCHEMBL1279773 | 0.82 | RAB9A (0.51) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL1696310 | 0.79 | MAP4K4 (0.50) | KMOLIMK1ATRMAP4K4CSNK2A1 | |
| SCHEMBL3717238 | 0.76 | PIK3CD (0.47) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL1279239 | 0.76 | DYRK1A (0.56) | NPC1RAB9ACSNK2A1 | |
| SCHEMBL1279505 | 0.76 | LCK (0.60) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL3716975 | 0.74 | PIK3CD (0.57) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL3855727 | 0.74 | ALDH1A1 (0.69) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL30526647 | 0.73 | MKNK1 (0.43) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL15587238 | 0.72 | MAP4K4 (0.74) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| CN-102480966-A | Fused heterocyclic compounds and uses thereof | NOVARTIS AG | 2012-05-30 | — | — | CN | disclosed |
| EP-2440058-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | KDM4E 4570/4885SMN1; SMN2 483/4885NFKB1 630/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | KDM4E 3923/4885SMN1; SMN2 198/4885NFKB1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.